Avalon Healthcare Solutions’ Client BCBS of South Carolina Adds CDx Diagnostics as In-Network Lab

CDx Diagnostics, Inc. is pleased to announce that it has signed an agreement with laboratory benefits management provider Avalon Healthcare Solutions, Inc. of Tampa, Fla. The agreement means that CDx will be an in-network specialty anatomic pathology laboratory of Avalon client BlueCross BlueShield of South Carolina, and builds on Avalon’s positive medical policy for CDx’s proprietary diagnostic platform, WATS^3D.

Data Privacy and Security: Chicago Public Schools Suffers Major Data Breach Affecting 100K Accounts

“This new agreement with Avalon brings modern, proven diagnostic technology to more than half a million more members. We will work together to bring this potentially lifesaving technology to additional payors and the members they serve.”

Short for wide-area transepithelial sampling with three-dimensional analysis, WATS^3D utilizes enhanced tissue acquisition, 3D imaging with AI-powered analysis, and expert pathologists to reliably detect Barrett’s esophagus (BE) and esophageal dysplasia. Effectively immediately, the agreement makes WATS^3D available to the 565,000 members of BCBS of South Carolina with all commercial and Medicare Advantage plans.

Top Machine Learning Insights: LivePerson Collaborates with UCSC to Build the Future of Natural…

“At CDx, we’re driven to empower physicians to preempt esophageal cancer and improve patient lives,” said Bill Huffnagle, CEO of CDx Diagnostics. “This new agreement with Avalon brings modern, proven diagnostic technology to more than half a million more members. We will work together to bring this potentially lifesaving technology to additional payors and the members they serve.”

WATS^3D technology helps clinicians overcome the limitations associated with traditional upper endoscopy screening and surveillance methods, by combining a specially designed brush, unique 3D imaging powered by AI, and a team of trained GI pathologists. In large multicenter clinical studies, WATS^3D has been found to significantly increase the detection rate of BE and esophageal dysplasia, both treatable precursors to esophageal cancer, one of the fastest growing and most fatal cancers in the United States.

Browse The Complete News About Aithority : Webex to Partner With Charliai to Further Enhance the Virtual Meeting Experience

[To share your insights with us, please write to sghosh@martechseries.com]